Stephen Pflugfelder, MD provided a number of dry eye pearls in his article, “Tear Dysfunction and the Cornea: LXVIII Edward Jackson Memorial Lecture” published inthe December 2011 issue of American Journal of Ophthalmology. http://www.ncbi.nlm.nih.gov/pubmed/22019306 Regarding osmolarity and its role in dry eye, Dr. … [Read more...]
Chronic BAK exposure is associated with an increase in tear osmolarity
January 27, 2012 By Leave a Comment
Dr. Eldridge began an interesting thread this past week regarding ocular surface disease in glaucoma patients. He reminded us that dry eye disease can often be silent in patients after chronic administration of BAK preservatives have reduced corneal … [Read more...]
Breakthrough in Diagnosing Dry Eye and Staging Disease Severity
January 24, 2012 By Leave a Comment
In January's edition of Cataract and Refractive Surgery Today, Jay Pepose, MD, PhD says.... A lot depends on treating patients with dry eye disease. Nearly one in five individuals in North America has dry eye disease (DED); it may be one of the most common yet frequently undiagnosed and untreated problems seen every day by … [Read more...]
TearLab Osmolarity System CLIA Waiver Issued By FDA
January 24, 2012 By Leave a Comment
SAN DIEGO, January 24, 2012 -- TearLab Corporation (NASDAQ:TEAR; TSX:TLB) ("TearLab" or the "Company") announced today that, after reviewing and accepting labeling submitted to it by the Company, the U.S Food and Drug Administration (“FDA”) has now granted Waiver categorization under the Clinical Laboratory Improvement … [Read more...]
Recent study shows preservative-free tafluprost offers effective treatment with less ocular surface impact for glaucoma patients
January 18, 2012 By Leave a Comment
We have known for years BAK is often a cause for ocular discomfort for patients. "Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma" in Clinical Ophthalmology Jan 2012 looks at tear osmolarity, corneal staining and OSDI in … [Read more...]
Diurnal variation of tear osmolarity in normal subjects measured by a new microchip system
January 11, 2012 By Leave a Comment
Normal subjects showed no variation over a day, confirming that a properly functioning tear film is characterized by its low and stable concentration. This study provides further evidence that eye-to-eye variability is the hallmark of Dry Eye Disease. As shown in Lemp et al. [AJO 2011], dry eye disease subjects showed … [Read more...]
ESTABLISHING A DRY EYE SUBSPECIALTY CLINIC
January 10, 2012 By Leave a Comment
See this weeks Practice Pearl from Paul Karpecki, OD where he discusses the many diagnostic instruments he would like to include in his "dream dry eye practice". He mentions the TearLab Osmolarity System, among others. http://www.revoptom.com/email/010912_pearl86_v2.html … [Read more...]
The Evolving Role of Biomarkers
January 5, 2012 By Leave a Comment
Biomarkers are becoming more and more important in patient care and this article by Elyse Chaglasian, OD presents multiple examples how eye care practitioners can care for their patients..... http://www.reviewofcontactlenses.com/content/c/31008/ … [Read more...]
The Advent of Tear Osmolarity
December 19, 2011 By Leave a Comment
The advent of tear osmolarity as a practical tool for diagnosis, determination of severity of disease and as a reliable objective measure of response to treatment is a game changer for clinicians faced daily in their offices with patients suffering from this disease. TearLab Corporation recently received a letter from the FDA … [Read more...]
TearLab Achieves Equal Reimbursement Across All States
December 14, 2011 By 1 Comment
December has turned out to be quite a month for TearLab Corporation. TearLab achieved their largest milestone last week when they received FDA communication granting them the CLIA waiver for the TearLab® Osmolarity System (pending labeling agreements). In addition, in a press release on Tuesday of this week, TearLab announced … [Read more...]
